Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen    QGEN   NL0012169213

QIAGEN

(QGEN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

QIAGEN : to deliver genomic insights for Japan's new molecular oncology clinical research and precision medicine initiative

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/18/2019 | 04:03pm EDT

Japan selects QIAGEN Clinical Insight-Interpret to handle next-generation sequencing data

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAGEN Clinical Insight (QCI) offering was selected by the National Cancer Center of Japan, as part of the Japan’s Ministry of Health, Labour and Welfare’s precision medicine program, for the analysis, interpretation and reporting of molecular oncology and oncogenetic screening of cancer patients to contribute to the identification of targeted therapy treatment and clinical trial options.

Japan’s Center for Cancer Genomics and Advanced Therapeutics (C-CAT), a unit within the National Cancer Center (NCC) of Japan, will use QIAGEN’s QCI platform including expert curated evidence knowledge bases, bioinformatics software and data center infrastructure to support the C-CAT’s molecular profiling services for core and cooperative hospitals of the country’s cancer genomic medicine program. QIAGEN has established an in-country data center in Tokyo, compliant with Japanese data security and privacy regulations, to support this national program.

QCI is a cloud-based clinical decision support software platform used to generate actionable insights from next-generation sequencing (NGS) data. QCI leverages QIAGEN’s expert manually curated evidence knowledge base that includes more than 10 million biomedical findings and thereby be far represents the world’s largest commercial database of curated evidence data on somatic and inherited genetic variants. QCI-Interpret minimizes the complexity and cost of determining the significance of NGS data and automates guidelines for clinical actionability from leading oncology and pathology organizations.

Please find the full press release here.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on QIAGEN
07/16QIAGEN N.V. : to Report Second Quarter and First Half of 2019 Results
BU
07/15QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
07/09QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/25QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/25QIAGEN : Clinical Insight surpasses 1 million patient test cases analyzed and in..
AQ
06/24QIAGEN N.V. : Release of a capital market information
EQ
06/21QIAGEN : New NGS panel for rare and inherited diseases with advanced bioinformat..
AQ
06/21QIAGEN : QCI-Lab performing expanded carrier screening boosts efficiency by 80%
AQ
06/20QIAGEN : Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed and In..
BU
More news
Financials (USD)
Sales 2019 1 578 M
EBIT 2019 430 M
Net income 2019 210 M
Debt 2019 771 M
Yield 2019 -
P/E ratio 2019 44,7x
P/E ratio 2020 35,0x
EV / Sales2019 6,15x
EV / Sales2020 5,54x
Capitalization 8 943 M
Chart QIAGEN
Duration : Period :
Qiagen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 42,23  $
Last Close Price 39,54  $
Spread / Highest target 26,5%
Spread / Average Target 6,81%
Spread / Lowest Target -8,95%
EPS Revisions
Managers
NameTitle
Peer Michael Schatz Chief Executive Officer & Managing Director
Sven Håkan Björklund Chairman-Supervisory Board
Douglas Liu Senior Vice President-Global Operations
Manuel O. Mendez Senior Vice President-Global Commercial Operations
Roland Sackers Chief Financial Officer & Managing Director
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN15.70%8 943
IQVIA HOLDINGS INC34.16%30 740
LONZA GROUP31.57%25 623
CELLTRION, INC.--.--%20 071
INCYTE CORPORATION26.66%17 271
EXACT SCIENCES CORPORATION85.26%14 835